Navigostics AG

Navigostics develops novel and highly efficient tumour analyses and algorithms to revolutionise personalised cancer diagnostics. The company produces diagnostic tests for various tumour indications that support treatment decisions for immunotherapies. To this end, Navignostics uses highly multiplexed, imaging tissue analysis methods that provide single-cell information to characterise tumour and immune cells and their interaction in the tissue. This data provides important information for predicting the success of immunotherapies. Navignostics AG is a spin-off of the University of Zurich founded in 2022.